In 2011, scientists developed a unique class of antivirals named DRACOs. DRACO proteins kill cells that are infected with viruses. One limitation to this technology is that DRACO proteins would also kill cells infected with benign viruses. Humans are often infected with benign viruses. We have modified DRACOs to specifically target cells infected with a disease-causing virus without harming regular cells. This novel strategy could be used more broadly against other disease-causing viruses.